Your browser doesn't support javascript.
loading
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Miravalle, Augusto A; Katz, Joshua; Robertson, Derrick; Hayward, Brooke; Harlow, Danielle E; Lebson, Lori A; Sloane, Jacob A; Bass, Ann D; Fox, Edward J.
Afiliação
  • Miravalle AA; Advanced Neurology of Colorado, University of Colorado, Fort Collins, CO 80528, USA.
  • Katz J; Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA 02481, USA.
  • Robertson D; Department of Neurology, Multiple Sclerosis Division, University of South Florida, Tampa, FL 33612, USA.
  • Hayward B; EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
  • Harlow DE; EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
  • Lebson LA; EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
  • Sloane JA; BIDMC Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.
  • Bass AD; Neurology Center of San Antonio, San Antonio, TX 78258, USA.
  • Fox EJ; Central Texas Neurology Consultants, Round Rock, TX 78681, USA.
Neurodegener Dis Manag ; 11(2): 99-111, 2021 04.
Article em En | MEDLINE | ID: mdl-33517769
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cladribina / Esclerose Múltipla Recidivante-Remitente / Imunossupressores Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cladribina / Esclerose Múltipla Recidivante-Remitente / Imunossupressores Idioma: En Ano de publicação: 2021 Tipo de documento: Article